Azenta, Inc. reported financial results for the fourth quarter and full fiscal year ended September 30, 2026, in a filing dated November 10, 2026. The company reported total revenue from continuing operations of $622 million for fiscal year 2026, representing a 5% increase compared to the prior year. On an organic basis, revenue growth was 2% for both the quarter and the full year. The company’s Sample Management Solutions segment generated $344 million in revenue for the year, up 6%, while the Multiomics segment reported $277 million, up 3%.
GAAP results for fiscal year 2026 showed an operating loss of $174.7 million, with diluted EPS from continuing operations at ($3.50). Adjusted diluted EPS was reported at $0.48. The company noted a non-cash goodwill impairment charge of $149 million contributing to the operating loss. Cash and liquidity as of September 30, 2026, totaled $506 million, with free cash flow for the year reaching $27 million.
Azenta provided guidance for fiscal year 2027, projecting total revenue between $648 million and $660 million. The company expects organic revenue growth to range between 3% and 5% year over year. Adjusted EBITDA margin is expected to expand by approximately 200 to 250 basis points compared to fiscal 2026.
In recent strategic developments, Azenta entered into agreements with Elegen Corp. on October 28, 2026, to expand gene synthesis capabilities, with an initial license payment of $23 million. The company also acquired SynPlexity Inc. for a base purchase price of $15 million, with potential additional payments contingent on revenue milestones.
